“Completed” is a status field, not a verdict. That distinction sounds obvious stated plainly. It gets lost constantly in how completed trials actually get read, by investors scanning a registry for a catalyst, by clinicians deciding what to trust, by this desk itself in earlier coverage, when a study shows COMPLETED next to a CNS or psychiatric indication and no results have been posted publicly.

Across this desk’s reporting this year, that same state has recurred among unrelated sponsors, phases, and institutions. The recurring instinct is to read the silence as a signal. The honest answer is that it is an information state, not an outcome, and the rules governing when that state should resolve are more specific, and more unevenly followed, than most coverage of clinical trial results assumes.

What “completed” actually promises, and what it doesn’t

A trial’s completion date on ClinicalTrials.gov marks when the last participant finished data collection for the primary outcome. It says nothing about database lock, when the sponsor finishes cleaning and finalizing that data, nothing about topline results, a sponsor’s own summary announcement, and nothing about peer-reviewed publication, which routinely lags both by months or years. These are sequential, not simultaneous, and a reader who treats “completed” as shorthand for “known” is reading past three separate steps that haven’t happened yet.

The rule, where one exists

Section 801 of the FDA Amendments Act of 2007 requires sponsors of what the law calls Applicable Clinical Trials, generally Phase 2 through 4 studies of an FDA-regulated drug or biologic, or most device trials, with a U.S. site or IND, to post summary results to ClinicalTrials.gov within 12 months of primary completion.

The exclusions matter as much as the rule itself. Phase 1 drug and biologic trials are not covered. Small device feasibility studies are not covered. Purely observational or noninterventional studies are not covered. A meaningful share of the completed-no-results trials observed this year sit in exactly this excluded territory, work with no statutory deadline attached at all, not evidence of anyone breaking a rule, because no rule applies.

Enforcement, where the rule does apply, has been close to theoretical. The penalty on the books, up to $10,000 per day of noncompliance, has essentially never been collected. Researcher Nicholas DeVito, who has spent years building public tooling to track this exact gap, put it to a reporter without much room for interpretation: to his knowledge, no fine has ever been issued. “If you’re not going to wield any of the power given to you by the law, the law is effectively neutered.”

That changed, at least in posture, this year. In March 2026, the FDA sent compliance reminders to more than 2,200 sponsors and researchers with overdue results. Whether that translates into actual penalties remains an open question this desk will keep watching, separate from anything in this piece.

The compliance data doesn’t converge on one number, and that’s the finding

Five independent analyses of FDAAA compliance, spanning different time periods, sponsor types, and disease areas, return meaningfully different figures. US government-sponsored trials had the lowest compliance of any sponsor class, 31.4 percent within one year, in one large cohort study, against 94 to 100 percent for the largest individual pharmaceutical sponsors, tracked by the same research group. A glioblastoma-specific cohort found 13 percent compliance within the 12-month deadline, rising to 82.7 percent within five years. A 2025 sponsor-level analysis put overall compliance at 37.2 percent, industry-only compliance at 73.7 percent, a figure that lines up closely with the FDA’s own internal estimate.

There is no single honest number to cite here. Sponsor type predicts compliance more strongly than almost anything else measured, and disease area, trial phase, and time window all move the figure further. A piece that reported “trials are typically X percent late” would be manufacturing precision the underlying research doesn’t have. The heterogeneity is not a gap in the data. It is what the data actually shows.

When the gap starts to mean something

Two situations produce genuinely different reads, and collapsing them into one is the most common mistake in how this status gets interpreted.

A trial completed eight months ago, still within the 12-month statutory window, with no results posted, is very likely routine. Nothing about that timeline should move anyone’s read of the underlying science.

A trial that passed its own required or expected disclosure deadline, whether that’s the 12-month statutory window for an Applicable Clinical Trial or a sponsor’s own previously stated milestone, and remains unposted on repeated checks, has moved into a different category. Not evidence of a bad outcome. Evidence that the normal clock has run out without the expected event happening, which is itself worth tracking, distinct from and prior to any conclusion about why.

What none of this licenses

No posted results does not mean a failed trial. Delayed publication does not mean concealment. Both of those readings require actual evidence beyond the absence itself, evidence this desk has not found in any of the CNS and psychiatric cases observed this year, and evidence this piece is not claiming exists. The honest vocabulary here is “results not yet publicly available,” “completed, results pending,” “disclosure gap.” Language implying hidden data or suppressed findings should require its own separate, direct evidence before it appears in copy, not an inference from a blank field on a registry page.

Why this belongs on a watchlist, not just in a single article

The stronger version of this story was never one silent trial. It’s the discipline of tracking a status, not an outcome, across a portfolio: completed, results pending, results posted, published, discontinued, treated as a structured category rather than a fact rediscovered one trial at a time. A single completed-no-results trial tells a reader almost nothing on its own. A structured view of which trials are still pending, how long they’ve been pending, and whether that duration has crossed a known threshold, tells a reader something closer to the actual maturity of the evidence base behind a given indication or mechanism, which is the thing investors, clinicians, and researchers actually need to gauge.

The caveats

The pattern behind this piece emerged from observations made across this desk’s reporting, but those observations were a lead, not evidence: every claim here rests on the independently verified regulatory materials and peer-reviewed compliance research cited above. Individual trials that first suggested the pattern are deliberately left out, because a status that cannot be confirmed cleanly across registry, sponsor, and phase should not appear stated as fact. That difficulty is the argument in miniature: disclosure status is harder to read precisely than a single registry field suggests.

Completed is where a trial’s data collection ends. It is not where a reader’s understanding of that trial should end too.